Wall Street Fundamentals Releases New In-Depth Stock Reports on ACAD, NPSP, SGMO and SRPT


Follow this company

Companies Mentioned

NASDAQ:ACAD / NASDAQ:NPSP / NASDAQ:SGMO / NASDAQ:SRPT
03/24/2014 [ACCESSWIRE]

Shares of major biotech companies stumbled Friday on concerns the sector may be overheated. The iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and the SPDR S&P Biotech ETF (NYSEARCA: XBI) posted declines of 4.74 percent and 4.18 percent Friday. "We still see more downside risk than upside reward for the sector given how extremely extended it has become on a longer-term timeframe," said MKM Partners' chief market technician, Jonathan Krinsky, in a note to clients.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares traded in the range of $25.60 to $28.25 Friday before settling to close at $26.01, a decrease of 6.61 percent. The stock appears to be facing some resistance at the $26.21 and $263.98 levels with some support at $25.39 and $24.93. Shares of ACADIA Pharmaceuticals are up approximately 4.0 percent year-to-date.

More information on ACADIA Pharmaceuticals and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/ACAD

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) shares traded in the range of $30.01 to $32.93 Friday before settling to close at $30.08, a decrease of 7.73 percent. The stock appears to be facing some resistance at the $30.94 and $31.88 levels with some support at $27.53 and $26.51. Shares of NPS Pharmaceuticals are down approximately 1.0 percent year-to-date.

More information on NPS Pharmaceuticals and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/NPSP

Sangamo Biosciences, Inc. (NASDAQ: SGMO) shares traded in the range of $20.99 to $22.56 Friday before settling to close at $21.35, a decrease of 7.58 percent. The stock appears to be facing some resistance at the $21.69 and $22.66 levels with some support at $19.85 and $18.38. Shares of Sangamo Biosciences are up approximately 53.0 percent year-to-date.

More information on Sangamo Biosciences and access to the free equity report can be found at:      
www.WallStreetFundamentals.com/SGMO

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares traded in the range of $26.54 to $28.45 Friday before settling to close at $26.60, a decrease of 4.80 percent. The stock appears to be facing some resistance at the $27.80 and $30.45 levels with some support at $22.72 and $20.78. Shares of Sarepta Therapeutics are up approximately 30.0 percent year-to-date.

More information on Sarepta Therapeutics and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/SRPT

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website:
www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com

COMMENTS

Leave a comment...
 * 

Your Name
 *